Scientific insight of real depth and value
If speed, precision, and quality rank high in your priorities, consider i3’s specialized approach: we tailor our processes and teams to meet the precise demands of your project and therapeutic category. This allows us to provide scientific insight of depth and value.
From common diagnoses such as angina, arrhythmia, and stroke to rarer illnesses, each condition examined in cardiology research demands specialized expertise. That is why we build your project team with precision and deliberation, and grant its members access to the largest global myocardial infarction registry with more than 2.5 million patients.
On every functional level, i3 professionals deliver scientific discipline, expertise, and dedication, making available to your development program an unmatched breadth and depth of knowledge.
Fully specialized—and carefully staffed—for project success
i3 brings extensive resources to this critical research area:
- Our therapeutic leads offer strategic thinking and stay involved at a high level of medical and scientific oversight throughout study execution
- Our clinical research experience includes Phases I–IV, INDs, clinical study reports, clinical development plans, pharmacoeconomic studies, and quality-of-life validation
- Our cardiology expertise is amplified by the experience of our clinical staff, including project managers, monitors, and advisors
As one of the leading therapeutic categories for clinical drug development, cardiology research is strategically important to i3—you’ll find our teams well-represented.
Our seamless integration of scientific, medical, and operations teams—combined with a unique eye on the therapeutic nuances—means every aspect of your study can be more efficient and exact.
Why i3?
- i3 maintains the largest global myocardial infarction registry with > 2.5 million patients
- Our recent experience spans a range of services in this diverse therapeutic category, including more than 26 studies ranging from niche studies in rare diseases to late-phase studies in more than 13,000 patients
- We have provided specialized services that include feasibility planning and protocol development, clinical monitoring, regulatory consulting, complete data management, and biostatistics—all on a global scale
|
